OM1 Launches Parkinson’s Disease Premium Dataset to Expand Real-World Evidence in Neuroscience

Read the full press release >>

BOSTON–(BUSINESS WIRE)–OM1, the leading real-world data and technology company focused on chronic conditions, today announced the launch of its Parkinson’s Disease (PD) premium dataset and the enhancement of its Mental Health & Neuroscience Real-World Data Network.

The dataset includes more than 7,000 patients prospectively followed by neurologists in hundreds of clinics across all 50 states. To enrich the data, OM1 extracts relevant information from treating clinician notes using its unique artificial intelligence (AI) and language modeling capabilities. Data points include key symptoms, disease severity, treatments, longitudinal outcomes, and clinical response. In addition to the premium dataset, data from an additional 700,000 PD patients are available in the OM1 Real-World Data Cloud™ for modeling health economics outcomes, patient recruitment for clinical trials, prescriber trends, and other research needs.

The dataset combines real-world data sources, such as electronic medical records (EMR), medical and pharmacy claims, mortality data and social determinants of health (SDoH), to provide deeper insights into Parkinson’s Disease patient journeys. The data can be leveraged to accelerate medical research and to support approvals and reimbursement, reducing the time to market and improving existing therapies.

This outcomes-enriched dataset comes at a critical time, as nearly 1 million Americans are living with Parkinson’s Disease, with experts arguing the number could be greater due to undiagnosed or misdiagnosed patients. There is currently no known cure and no interventions that meaningfully reduce the progression of the disease. While some medications can help control or lessen symptoms, these medications are most effective in the early stages.

“Understanding treatments and disease progression in patients suffering from this devastating illness with real-world data is critical for driving clinical advancements,” said Carl Marci, MD, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. “Among our goals is to break down barriers that impede access to deep clinical insights that otherwise would go unseen and unused to help develop personalized and targeted treatments for patients with Parkinson’s Disease.”

OM1’s Mental Health & Neuroscience Real-World Data Network, which already includes robust datasets focused on Major Depressive Disorder, Multiple Sclerosis, Bipolar Disorder I and Schizophrenia, will further expand to include Alzheimer’s Disease in the coming months. To learn more about the largest mental health and neuroscience data network in the U.S., please email info@om1.com.